Outpatient Use of Monoclonal Antibodies Casirivimab and Imdevimab in Pregnancy for Mild-to-Moderate Coronavirus Disease 2019
Thieme. All rights reserved..
OBJECTIVE: The aim of this study was to report the use casirivimab/imdevimab therapy in pregnant women with moderate coronavirus disease 2019 (COVID-19).
STUDY DESIGN: We report 12 cases of unvaccinated pregnant patients with mild-to-moderate COVID-19 treated with casirivimab/imdevimab.
RESULTS: Twelve unvaccinated pregnant patients with mild-to-moderate COVID-19 received casirivimab/imdevimab at the dose of 1200/1200 mg by intravenous infusion over 60 minutes. All women were managed outpatient. None experienced severe adverse drug reaction and none progressed to severe disease.
CONCLUSION: Casirivimab/imdevimab should be considered for outpatient treatment of unvaccinated pregnant women with mild-to-moderate COVID-19 to decrease the risk of severe disease.
KEY POINTS: · Casirivimab/imdevimab is not well studied in pregnant women.. · Casirivimab/imdevimab in pregnant women with mild-to-moderate COVID-19 decreases the risk of severe disease.. · Casirivimab/imdevimab in pregnant women with mild-to-moderate COVID-19 is well tolerated.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:41 |
|---|---|
| Enthalten in: |
American journal of perinatology - 41(2024), 3 vom: 14. Feb., Seite 365-367 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Buonomo, Antonio Riccardo [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 08.02.2024 Date Revised 08.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1055/s-0042-1753488 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355758911 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355758911 | ||
| 003 | DE-627 | ||
| 005 | 20240208231835.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1055/s-0042-1753488 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1284.xml |
| 035 | |a (DE-627)NLM355758911 | ||
| 035 | |a (NLM)37072016 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Buonomo, Antonio Riccardo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Outpatient Use of Monoclonal Antibodies Casirivimab and Imdevimab in Pregnancy for Mild-to-Moderate Coronavirus Disease 2019 |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.02.2024 | ||
| 500 | |a Date Revised 08.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Thieme. All rights reserved. | ||
| 520 | |a OBJECTIVE: The aim of this study was to report the use casirivimab/imdevimab therapy in pregnant women with moderate coronavirus disease 2019 (COVID-19) | ||
| 520 | |a STUDY DESIGN: We report 12 cases of unvaccinated pregnant patients with mild-to-moderate COVID-19 treated with casirivimab/imdevimab | ||
| 520 | |a RESULTS: Twelve unvaccinated pregnant patients with mild-to-moderate COVID-19 received casirivimab/imdevimab at the dose of 1200/1200 mg by intravenous infusion over 60 minutes. All women were managed outpatient. None experienced severe adverse drug reaction and none progressed to severe disease | ||
| 520 | |a CONCLUSION: Casirivimab/imdevimab should be considered for outpatient treatment of unvaccinated pregnant women with mild-to-moderate COVID-19 to decrease the risk of severe disease | ||
| 520 | |a KEY POINTS: · Casirivimab/imdevimab is not well studied in pregnant women.. · Casirivimab/imdevimab in pregnant women with mild-to-moderate COVID-19 decreases the risk of severe disease.. · Casirivimab/imdevimab in pregnant women with mild-to-moderate COVID-19 is well tolerated | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a casirivimab and imdevimab drug combination |2 NLM | |
| 650 | 7 | |a casirivimab |2 NLM | |
| 650 | 7 | |a J0FI6WE1QN |2 NLM | |
| 650 | 7 | |a imdevimab |2 NLM | |
| 650 | 7 | |a 2Z3DQD2JHM |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a Drug Combinations |2 NLM | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 700 | 1 | |a Filippo, Isabella Di |e verfasserin |4 aut | |
| 700 | 1 | |a Esposito, Nunzia |e verfasserin |4 aut | |
| 700 | 1 | |a Saccone, Gabriele |e verfasserin |4 aut | |
| 700 | 1 | |a Nobile, Mariano |e verfasserin |4 aut | |
| 700 | 1 | |a Viceconte, Giulio |e verfasserin |4 aut | |
| 700 | 1 | |a Villari, Riccardo |e verfasserin |4 aut | |
| 700 | 1 | |a Carlo, Costantino Di |e verfasserin |4 aut | |
| 700 | 1 | |a Bifulco, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Gentile, Ivan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t American journal of perinatology |d 1993 |g 41(2024), 3 vom: 14. Feb., Seite 365-367 |w (DE-627)NLM013020544 |x 1098-8785 |7 nnns |
| 773 | 1 | 8 | |g volume:41 |g year:2024 |g number:3 |g day:14 |g month:02 |g pages:365-367 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1055/s-0042-1753488 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 41 |j 2024 |e 3 |b 14 |c 02 |h 365-367 | ||